Endo Launches Ibuprofen-Famotidine Tablets, Generic Version of DUEXIS®
Endo Reports Fourth-Quarter 2023 Financial Results
Endo agreed to pay up to $464.9 million to resolve claims around the marketing of its former opioid pain medication Opana ER.
Editor's note: This story was updated to note that Endo's criminal and civil opioid settlement payments will be satisfied by the bankruptcy resolution, according to an Endo spokesperson.
DUBLIN, Jan. 24, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that the peer-reviewed Journal of Hand Surgery Global Open published Collagenase Clostridium Histolyticum for the Treatment of Dupuytren Disease: A Delphi-Based Consensus Study.1